{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:21:47Z","timestamp":1768738907612,"version":"3.49.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0127048","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T17:56:01Z","timestamp":1431453361000},"page":"e0127048","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":42,"title":["Nano-LC-MS\/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease"],"prefix":"10.1371","volume":"10","author":[{"given":"Hideaki","family":"Sueoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"ref1","first-page":"3733","article-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"RJ Desnick","year":"2001"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archneur.63.3.453","article-title":"Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome","volume":"63","author":"CS Nance","year":"2006","journal-title":"Arch Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"KD MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"R Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"CM Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"E Young","year":"2005","journal-title":"Acta Paediatr"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"JM Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"SM Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"MJ van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"T Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase A mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"J Lukas","year":"2013","journal-title":"PLoS Genet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymgme.2012.07.003","article-title":"Mutant \u03b1-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level","volume":"107","author":"S Mitobe","year":"2012","journal-title":"Mol Genet Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883\u2013884","author":"R Kr\u00fcger","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of Fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"H Gold","year":"2013","journal-title":"Clin Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"M Boutin","year":"2012","journal-title":"Clin Chim Acta"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"P Lavoie","year":"2013","journal-title":"Anal Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb3-related analogues in Fabry disease","volume":"86","author":"M Boutin","year":"2014","journal-title":"Anal Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"C Auray-Blais","year":"2012","journal-title":"Anal Chem"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/092986713804806685","article-title":"A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers","volume":"20","author":"FO Dupont","year":"2013","journal-title":"Curr Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/ac00168a006","article-title":"Separation efficiency of slurry-packed liquid chromatography microcolumns with very small inner diameters","volume":"60","author":"KE Karson","year":"1988","journal-title":"Anal Chem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chroma.2004.10.107","article-title":"Proteomic LC-MS systems using nanoscale liquid chromatography with tandem mass spectrometry","volume":"1067","author":"Y Ishihama","year":"2005","journal-title":"J Chromatogr A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chemphyslip.2011.04.011","article-title":"Nano-liquid chromatography-tandem mass spectrometry analysis of oxysterols in brain: monitoring of cholesterol autoxidation","volume":"164","author":"K Karu","year":"2011","journal-title":"Chem Phys Lipids"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.talanta.2013.07.057","article-title":"Nano-LC-MS\/MS for the quantitation of ceramides in mice cerebrospinal fluid using minimal sample volume","volume":"116","author":"D Thomas","year":"2013","journal-title":"Talanta"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/rcm.6628","article-title":"Comparison of the quantitative performance of a Q-Exactive high-resolution mass spectrometer with that of a triple quadrupole tandem mass spectrometer for the analysis of illicit drugs in wastewater","volume":"27","author":"G Fedorova","year":"2013","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/ejoc.201001690","article-title":"A concise synthesis of globotriaosylsphingosine","author":"H Gold","year":"2011","journal-title":"Eur J Org Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/jhg.2010.58","article-title":"Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns","volume":"55","author":"BH Lee","year":"2010","journal-title":"J Hum Genet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ymgme.2012.01.010","article-title":"Fabry disease: biochemical, pathological and structural studies of the \u03b1-galactosidase A with E66Q amino acid substitution","volume":"105","author":"T Togawa","year":"2012","journal-title":"Mol Genet Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"CM Eng","year":"1994","journal-title":"Hum Mol Genet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"S Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ymgmr.2014.07.005","article-title":"Plasma mutant \u03b1-galactosidase A protein and globotriaosylsphingosine level in Fabry disease","volume":"1","author":"T Tsukimura","year":"2014","journal-title":"Mol Genet Metab Reports"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"M Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0127048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T09:05:02Z","timestamp":1540026302000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0127048"}},"subtitle":[],"editor":[{"given":"Claudia","family":"Sommer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0127048","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}